Cargando…

Cyclodextrin-Modified Nanomaterials for Drug Delivery: Classification and Advances in Controlled Release and Bioavailability

In drug delivery, one widely used way of overcoming the biopharmaceutical problems present in several active pharmaceutical ingredients, such as poor aqueous solubility, early instability, and low bioavailability, is the formation of inclusion compounds with cyclodextrins (CD). In recent years, the...

Descripción completa

Detalles Bibliográficos
Autores principales: Real, Daniel Andrés, Bolaños, Karen, Priotti, Josefina, Yutronic, Nicolás, Kogan, Marcelo J., Sierpe, Rodrigo, Donoso-González, Orlando
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8706493/
https://www.ncbi.nlm.nih.gov/pubmed/34959412
http://dx.doi.org/10.3390/pharmaceutics13122131
_version_ 1784622206130585600
author Real, Daniel Andrés
Bolaños, Karen
Priotti, Josefina
Yutronic, Nicolás
Kogan, Marcelo J.
Sierpe, Rodrigo
Donoso-González, Orlando
author_facet Real, Daniel Andrés
Bolaños, Karen
Priotti, Josefina
Yutronic, Nicolás
Kogan, Marcelo J.
Sierpe, Rodrigo
Donoso-González, Orlando
author_sort Real, Daniel Andrés
collection PubMed
description In drug delivery, one widely used way of overcoming the biopharmaceutical problems present in several active pharmaceutical ingredients, such as poor aqueous solubility, early instability, and low bioavailability, is the formation of inclusion compounds with cyclodextrins (CD). In recent years, the use of CD derivatives in combination with nanomaterials has shown to be a promising strategy for formulating new, optimized systems. The goals of this review are to give in-depth knowledge and critical appraisal of the main CD-modified or CD-based nanomaterials for drug delivery, such as lipid-based nanocarriers, natural and synthetic polymeric nanocarriers, nanosponges, graphene derivatives, mesoporous silica nanoparticles, plasmonic and magnetic nanoparticles, quantum dots and other miscellaneous systems such as nanovalves, metal-organic frameworks, Janus nanoparticles, and nanofibers. Special attention is given to nanosystems that achieve controlled drug release and increase their bioavailability during in vivo studies.
format Online
Article
Text
id pubmed-8706493
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87064932021-12-25 Cyclodextrin-Modified Nanomaterials for Drug Delivery: Classification and Advances in Controlled Release and Bioavailability Real, Daniel Andrés Bolaños, Karen Priotti, Josefina Yutronic, Nicolás Kogan, Marcelo J. Sierpe, Rodrigo Donoso-González, Orlando Pharmaceutics Review In drug delivery, one widely used way of overcoming the biopharmaceutical problems present in several active pharmaceutical ingredients, such as poor aqueous solubility, early instability, and low bioavailability, is the formation of inclusion compounds with cyclodextrins (CD). In recent years, the use of CD derivatives in combination with nanomaterials has shown to be a promising strategy for formulating new, optimized systems. The goals of this review are to give in-depth knowledge and critical appraisal of the main CD-modified or CD-based nanomaterials for drug delivery, such as lipid-based nanocarriers, natural and synthetic polymeric nanocarriers, nanosponges, graphene derivatives, mesoporous silica nanoparticles, plasmonic and magnetic nanoparticles, quantum dots and other miscellaneous systems such as nanovalves, metal-organic frameworks, Janus nanoparticles, and nanofibers. Special attention is given to nanosystems that achieve controlled drug release and increase their bioavailability during in vivo studies. MDPI 2021-12-10 /pmc/articles/PMC8706493/ /pubmed/34959412 http://dx.doi.org/10.3390/pharmaceutics13122131 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Real, Daniel Andrés
Bolaños, Karen
Priotti, Josefina
Yutronic, Nicolás
Kogan, Marcelo J.
Sierpe, Rodrigo
Donoso-González, Orlando
Cyclodextrin-Modified Nanomaterials for Drug Delivery: Classification and Advances in Controlled Release and Bioavailability
title Cyclodextrin-Modified Nanomaterials for Drug Delivery: Classification and Advances in Controlled Release and Bioavailability
title_full Cyclodextrin-Modified Nanomaterials for Drug Delivery: Classification and Advances in Controlled Release and Bioavailability
title_fullStr Cyclodextrin-Modified Nanomaterials for Drug Delivery: Classification and Advances in Controlled Release and Bioavailability
title_full_unstemmed Cyclodextrin-Modified Nanomaterials for Drug Delivery: Classification and Advances in Controlled Release and Bioavailability
title_short Cyclodextrin-Modified Nanomaterials for Drug Delivery: Classification and Advances in Controlled Release and Bioavailability
title_sort cyclodextrin-modified nanomaterials for drug delivery: classification and advances in controlled release and bioavailability
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8706493/
https://www.ncbi.nlm.nih.gov/pubmed/34959412
http://dx.doi.org/10.3390/pharmaceutics13122131
work_keys_str_mv AT realdanielandres cyclodextrinmodifiednanomaterialsfordrugdeliveryclassificationandadvancesincontrolledreleaseandbioavailability
AT bolanoskaren cyclodextrinmodifiednanomaterialsfordrugdeliveryclassificationandadvancesincontrolledreleaseandbioavailability
AT priottijosefina cyclodextrinmodifiednanomaterialsfordrugdeliveryclassificationandadvancesincontrolledreleaseandbioavailability
AT yutronicnicolas cyclodextrinmodifiednanomaterialsfordrugdeliveryclassificationandadvancesincontrolledreleaseandbioavailability
AT koganmarceloj cyclodextrinmodifiednanomaterialsfordrugdeliveryclassificationandadvancesincontrolledreleaseandbioavailability
AT sierperodrigo cyclodextrinmodifiednanomaterialsfordrugdeliveryclassificationandadvancesincontrolledreleaseandbioavailability
AT donosogonzalezorlando cyclodextrinmodifiednanomaterialsfordrugdeliveryclassificationandadvancesincontrolledreleaseandbioavailability